Novel HIV Integrase Inhibitor Compounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV treatment therapies face challenges due to resistance issues with existing drugs targeting reverse transcriptase and protease enzymes, necessitating the development of new antiretroviral compounds that effectively inhibit HIV replication.
Innovation Solution
Development of novel compounds with inhibitory activity against HIV replication, specifically targeting the HIV integrase enzyme, which can be used to reduce HIV replication and treat HIV infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing drugs targeting reverse transcriptase and protease enzymes are used, then HIV replication is inhibited, but resistance to these drugs develops
Solution Approach 1:
The patent changes the target parameter from reverse transcriptase/protease enzymes to integrase enzyme, representing a fundamental shift in the biochemical parameter being targeted. This allows inhibition of HIV replication through a different mechanism that does not induce resistance to existing reverse transcriptase or protease inhibitors
Solution Approach 2:
The patent introduces integrase enzyme as an intermediary target in the HIV replication pathway. Instead of directly targeting reverse transcriptase or protease, the compounds mediate inhibition through integrase, which processes viral DNA integration into host genome, providing a new therapeutic avenue that avoids cross-resistance
2Adaptability or versatility
If new antiretroviral compounds targeting integrase are developed, then resistance issues are avoided, but development complexity increases
Solution Approach 1:
The patent segments the HIV treatment approach by isolating and targeting the integrase step in the viral replication cycle separately from reverse transcriptase and protease inhibition. This segmentation allows for specialized compound design focused solely on integrase active site interactions, simplifying the development pathway for integrase-specific inhibitors
Solution Approach 2:
The patent employs systematic parameter changes in the chemical structure of integrase inhibitors, varying substituents at specific positions (R1-R6) to optimize binding affinity and selectivity for the integrase enzyme while maintaining manageable synthesis complexity
Data Source
AI summary
Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.